Galactomannan and 1, 3-β-D-Glucan Assay in Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Malignant and Non-malignant Patients
DOI:
https://doi.org/10.3889/oamjms.2021.5994Keywords:
Invasive pulmonary aspergillosis, Invasive fungal infections, Galactomannan (GM), 1, 3-β-D-Glucan (BDG), Bronchoalveolar lavage, Fungal infection in hematological malignanciesAbstract
BACKGROUND: Serum 1, 3-β-D-glucan (BDG) assay was recommended for diagnosing fungal infections.
AIM: We aimed to assess 1, 3-β-D-glucan in bronchoalveolar lavage (BAL) fluid in invasive pulmonary aspergillosis (IPA).
METHODS: Out of 104 patients clinically suspected fungal, 45 were probable, 18 possible, and 41 unlikely according to EORTC/MSG 2008 criteria. Measuring BAL BDG and galactomannan were done.
RESULTS: The sensitivity, specificity, and positive and negative predictive values (PPV and NPV) for BDG were 44%, 71%, 62%, and 54%; for galactomannan 84%, 83%, 84%, and 83%; and 93%, 66%, 75%, and 90%, respectively, when combining both tests. A significant different performance of GM; p = 0.0008 was detected in patients with malignant disorders when compared to non-malignant; but not for BDG; p = 0.121.
CONCLUSION: We can conclude that BAL-BDG is helpful if positive in a clinically suspected IFI case, but if negative cannot rule out fungal infection. Thus, combining results of BAL-GM and BAL-BDG are recommended.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Bassetti M, Garnacho-Montero J, Calandra T, Kullberg B, Dimopoulos G, Azoulay E, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017;43(9):1225-38. https://doi.org/10.1007/s00134-017-4731-2 PMid:28255613 DOI: https://doi.org/10.1007/s00134-017-4731-2
Patterson TF, Thompson GR, Denning DW, Fishman J, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2016;63(4):433-42. https://doi.org/10.1093/cid/ciw444 PMid:27365388 DOI: https://doi.org/10.1093/cid/ciw444
Chu YF. Oats Nutrition and Technology. Barrington, Illinois: Wiley Blackwell; 2014. DOI: https://doi.org/10.1002/9781118354100
Odabasi Z, Paetznick V, Rodriguez J, Chen E, McGinnis M, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol. 2006;44(3):267-72. https://doi.org/10.1080/13693780500474327 PMid:16702107 DOI: https://doi.org/10.1080/13693780500474327
Marty F, Koo S. Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2009;47(Suppl 1):S233-40. https://doi.org/10.1080/13693780802308454 PMid:18720216 DOI: https://doi.org/10.1080/13693780802308454
De Pauw B, Walsh TJ, Donnelly JP, Stevens D, Edwards J, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21. https://doi.org/10.3410/f.1116756.572830 PMid:18462102 DOI: https://doi.org/10.3410/f.1116756.572830
El-Mahallawy H, Shaker H, Helmy H, Mostafa T, Abo-Sedah A. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol. 2006;44(8):733-9. https://doi.org/10.1080/13693780600939955 PMid:17127630 DOI: https://doi.org/10.1080/13693780600939955
Park S, Yoon J, Kim SH. Voriconazole-refractory invasive aspergillosis. Korean J Intern Med. 2017;32(5):805-12. https://doi.org/10.3904/kjim.2017.109 PMid:28835093 DOI: https://doi.org/10.3904/kjim.2017.109
Boch T, Spiess B, Cornely OA, Vehreschild JJ, Rath PM, Steinmann J, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: Results of a prospective multicentre study. Clin Microbiol Infect. 2016;22(10):862-8. https://doi.org/10.1016/j.cmi.2016.06.021 PMid:27393123 DOI: https://doi.org/10.1016/j.cmi.2016.06.021
Zou M, Tang L, Zhao Z, Chen L, Chen P, Huang Z, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One. 2012;7(8):e43347. https://doi.org/10.1371/journal.pone.0043347 PMid:22905261 DOI: https://doi.org/10.1371/journal.pone.0043347
Hoenigl M, Prattes J, Spiess B, Wagner J, Prueller F, Raggam R, et al. Performance of galactomannan, beta-D-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014;52(6):2039-45. https://doi.org/10.1128/jcm.00467-14 PMid:24671798 DOI: https://doi.org/10.1128/JCM.00467-14
Cefalo M, Puxeddu E, Samati L, Paterno G, Fontana C, Nasso D, et al. Diagnostic performance and safety of bronchoalveolar lavage in thrombocytopenic haematological patients for invasive fungal infections diagnosis: A monocentric, retrospective experience. Mediterr J Hematol Infect Dis. 2019;11(1):e2019065. https://doi.org/10.4084/mjhid.2019.065 PMid:31700590 DOI: https://doi.org/10.4084/mjhid.2019.065
Pichun MB, Raed S, Gea-Banacloche JC. Infectious complications in oncology. In: Abraham J, Gulley JL, Allegra CJ, Pine JW, editors. The Bethesda Handbook of Clinical Oncology. Clevland: Lippincott Williams and Wilkins; 2014. p. 448-67.
Shi XY, Liu Y, Gu XM, Hao SY, Wang YH, Jiang SJ. Diagnostic value of (1 → 3)-β-D-glucan in bronchoalveolar lavage fluid for invasive fungal disease: A meta-analysis. Respir Med. 2016;117:48-53. https://doi.org/10.1016/j.rmed.2016.05.017 PMid:27492513 DOI: https://doi.org/10.1016/j.rmed.2016.05.017
White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev. 2020;7(7):CD009833. https://doi.org/10.1002/14651858.cd009833.pub2 PMid:32693433 DOI: https://doi.org/10.1002/14651858.CD009833.pub2
Rose SR, Vallabhajosyula S, Velez MG, Fedorko D, VanRaden M, Gea-Banacloche J, et al. The utility of bronchoalveolar lavage beta-d-glucan testing for the diagnosis of invasive fungal infection. J Infect. 2014;69(3):278-83. https://doi.org/10.1016/j.jinf.2014.04.008 PMid:24797077 DOI: https://doi.org/10.1016/j.jinf.2014.04.008
Prattes J, Flick H, Pruller F, Koidl C, Raggam R, Palfner M, et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med. 2014;190(8):922-9. https://doi.org/10.1164/rccm.201407-1275oc PMid:25203869 DOI: https://doi.org/10.1164/rccm.201407-1275OC
Mahmoud E, El-Din MM, Hafez M, Sobh E, Ibrahim R. Pulmonary fungal infection in patients with acute exacerbation of chronic obstructive pulmonary disease. Sci J Al Azhar Med Fac Girl. 2019;3:7-13. https://doi.org/10.4103/sjamf.sjamf_37_18 DOI: https://doi.org/10.4103/sjamf.sjamf_37_18
Lamoth F. Galactomannan and 1,3-β-D-glucan Testing for the diagnosis of invasive aspergillosis. J Fungi (Basel). 2016;2(3):22. https://doi.org/10.3390/jof2030022 PMid:29376937 DOI: https://doi.org/10.3390/jof2030022
Downloads
Published
How to Cite
License
Copyright (c) 2021 Hadir Ahmed El-Mahallawy, Rana El-Gendi, Doaa Mohammad Ghaith, Iman Kamal Behiry, Soheir Fathy Helal (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
